Abstract
Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Volume: 13 Issue: 2
Author(s): Wilbert S. Aronow
Affiliation:
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Abstract: Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Export Options
About this article
Cite this article as:
Aronow S. Wilbert, Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1871529X11313020008
DOI https://dx.doi.org/10.2174/1871529X11313020008 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress, Sarcopenia, Antioxidant Strategies and Exercise: Molecular Aspects
Current Pharmaceutical Design Critical Role of Hypoxia Sensor - HIF-1α in VEGF Gene Activation. Implications for Angiogenesis and Tissue Injury Healing
Current Medicinal Chemistry Cellular and Pharmacological Targets to Induce Coronary Arteriogenesis
Current Cardiology Reviews Prediction of Nitration Sites Based on FCBF Method and Stacking Ensemble Model
Current Proteomics Protective Effect of Vitamin B Therapy on Bone and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis
Recent Patents on Drug Delivery & Formulation Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Role of Vascular Cell Senescence in Atherosclerosis: Antisenescence as a Novel Therapeutic Strategy for Vascular Aging
Current Vascular Pharmacology Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Oxidative Stress and NAD+ in Ischemic Brain Injury: Current Advances and Future Perspectives
Current Medicinal Chemistry Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Shedding Light on the Pathophysiology of Preeclampsia-Syndrome in the Era of Cardio-Obstetrics: Role of Inflammation and Endothelial Dysfunction
Current Hypertension Reviews Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design